PSMA PET/CT联合多参数MRI在前列腺癌诊断中的附加诊断价值:PRIMARY前瞻性多中心研究
PRIMARY试验为前瞻性多中心II期影像研究,纳入291例疑似前列腺癌且未活检男性,比较MRI、PSMA及PSMA+MRI对临床显著前列腺癌(csPCa)的诊断效能。PSMA+MRI较MRI提高阴性预测值(91% vs 72%)和敏感性(97% vs 83%),但特异性降低(40% vs 53%),19%患者可潜在避免活检。
要点
- PSMA+MRI较MRI提高csPCa阴性预测值至91%,可减少不必要活检。
- 联合策略敏感性97%但特异性降至40%,需权衡过度诊断风险。
- 19%患者联合影像阴性可潜在免活检,延迟诊断csPCa风险1.7%。
核心结论
- 在MRI分诊人群中,PSMA+MRI较MRI提高csPCa的阴性预测值和敏感性,但降低特异性。
研究设计与样本
- 前瞻性多中心II期影像试验,纳入296例疑似前列腺癌男性,291例完成MRI、盆腔PSMA及系统±靶向活检。
主要发现
- 56%(162例)患者为csPCa;67% PI-RADS 3-5,73% PSMA阳性,81%联合阳性。
- PSMA+MRI较MRI提高阴性预测值(91% vs 72%,检验比=1.27[1.11-1.39],p<0.001)。
- PSMA+MRI较MRI提高敏感性(97% vs 83%,p<0.001)但降低特异性(40% vs 53%,p=0.011)。
- 联合影像漏诊5例csPCa(4例ISUP 2,1例ISUP 3)。
- 19%(56/291)患者联合阴性可潜在免活检,延迟诊断csPCa风险3.1%(5/162)或总体1.7%(5/291)。
关键数值与推荐
- PSMA+MRI阴性定义为PSMA阴性且PI-RADS 2/3;阳性定义为MRI PI-RADS 4/5或PSMA阳性且PI-RADS 2/3。
- csPCa定义为ISUP分级组≥2的恶性肿瘤。
临床怎么用
- 对于临床怀疑csPCa但联合影像阴性的男性,可考虑避免活检,但需进一步随机研究确认安全性。
局限性
- 联合影像仍漏诊5例csPCa,需权衡延迟诊断风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Multiparametric magnetic resonance imaging (MRI) is validated for the detection of clinically significant prostate cancer (csPCa), although patients with negative/equivocal MRI undergo biopsy for false negative concerns. In addition, 68Ga-PSMA-11 positron emission tomography/computed tomography (prostate-specific membrane antigen [PSMA]) may also identify csPCa accurately. OBJECTIVE: This trial aimed to determine whether the combination of PSMA + MRI was superior to MRI in diagnostic performance for detecting csPCa. DESIGN, SETTING, AND PARTICIPANTS: A prospective multicentre phase II imaging trial was conducted. A total of 296 men were enrolled with suspected prostate cancer, with no prior biopsy or MRI, recent MRI (6 mo), and planned transperineal biopsy based on clinical risk and MRI. In all, 291 men underwent MRI, pelvic-only PSMA, and systematic ± targeted biopsy. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Sensitivity, specificity, and predictive values (negative predictive value [NPV] and positive predictive value) for csPCa were determined for MRI, PSMA, and PSMA + MRI. PSMA + MRI was defined as negative for PSMA negative Prostate Imaging Reporting and Data System (PI-RADS) 2/3 and positive for either MRI PI-RADS 4/5 or PSMA positive PI-RADS 2/3; csPCa was any International Society of Urological Pathology (ISUP) grade group ≥2 malignancy. RESULTS AND LIMITATIONS: Of the patients, 56% (n = 162) had csPCa; 67% had PI-RADS 3-5, 73% were PSMA positive, and 81% were combined PSMA + MRI positive. Combined PSMA + MRI improved NPV compared with MRI alone (91% vs 72%, test ratio = 1.27 [1.11-1.39], p < 0.001). Sensitivity also improved (97% vs 83%, p < 0.001); however, specificity was reduced (40% vs 53%, p = 0.011). Five csPCa cases were missed with PSMA + MRI (four ISUP 2 and one ISUP 3). Of all men, 19% (56/291) were PSMA + MRI negative (38% of PI-RADS 2/3) and could potentially have avoided biopsy, risking delayed csPCa detection in 3.1% men with csPCa (5/162) or 1.7% (5/291) overall. CONCLUSIONS: PSMA + MRI improved NPV and sensitivity for csPCa in an MRI triaged population. Further randomised studies will determine whether biopsy can safely be omitted in men with a high clinical suspicion of csPCa but negative combined imaging. PATIENT SUMMARY: The combination of magnetic resonance imaging (MRI) + prostate-specific membrane antigen positron emission tomography reduces false negatives for clinically significant prostate cancer (csPCa) compared with MRI, potentially allowing a reduction in the number of prostate biopsies required to diagnose csPCa.
引用
- Emmett L, Buteau J, Papa N, et al. The Additive Diagnostic Value of Prostate-specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study. Eur Urol. 2021. PMID: 34465492. doi:10.1016/j.eururo.2021.08.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。